TCR based autologous cell therapy program(Treadwell Therapeutics)

N/A

Report date: 2024/03/04 10:15:19

Base Information

Drug NameTCR based autologous cell therapy program(Treadwell Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTreadwell Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTreadwell Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A